Back

Discussion and summary - LDL-c: done deal, next epigenetics? .

25 August 2018 (16:25 - 16:30)
Organised by:
Congress Presentation Part of: LDL-c: done deal, next epigenetics? (EBAC Accredited) Secondary Prevention ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Ulrich Laufs

University Hospital Leipzig, Leipzig (Germany)

4 More presentations in this session

Presentation thumbnail
Introduction - LDL-c: done deal, next epigenetics?
Professor U. Laufs (Leipzig, DE)
Presentation thumbnail
The real residual risk in patients with cardiovascular disease and diabetes: the promise of epigenetics.
Professor E. Stroes (Amsterdam, NL)
Presentation thumbnail
Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.
Doctor J. Plutzky (Boston, US)
Presentation thumbnail
A clinical view on BET inhibition in targeting residual risk in cardiovascular disease and diabetes.
Professor K. Ray (London, GB)

Access the full session

Session thumbnail
LDL-c: done deal, next epigenetics? (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

25 August 2018 16:25 CET
You may be interested in
thumbnail
Webinar
Biomarkers of clinical utility in cardiovascular disease
17 December 2024
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
30 August 2021
thumbnail
Congress Presentation
The cardiac epigenome encodes racial and socioeconomic differences among patients with end-stage heart failure
29 June 2021
thumbnail
Congress Session
Epigenetic regulators and tools
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources